Pemvidutide
Also known as: ALT-801
Dual GLP-1/glucagon receptor agonist designed for MASH and obesity; glucagon component drives hepatic fat oxidation.
- Typical dose
- 1.2 mg – 2.4 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 6 days
- Routes
- Subcutaneous
- Status
- Investigational: Phase II (Breakthrough Therapy Designation)
Benefits
- Liver fat reduction
- Weight loss
- MASH treatment
- Improved lipid profile
Dosing
A common research range for Pemvidutide is 1.2 mg to 2.4 mg once weekly. Weekly injection; titrate over 4 weeks. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Pemvidutide has an approximate half-life of 6 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Diarrhea
- Vomiting
Contraindications
- MEN2
- Pancreatitis
Track Pemvidutide with Vial
Vial logs every Pemvidutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Pemvidutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.